Compare Moderna, Inc. (MRNA) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Open Text Corporation — how do they compare? Moderna, Inc. trades at $221.99 (market cap $78.65B), while Open Text Corporation trades at $23.7 (market cap $5.61B). The key difference: Moderna, Inc. is far larger — about 14× Open Text Corporation's market cap, and Open Text Corporation pays a 4.82% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Open Text Corporation for 23 Days on average.
| MRNA | OTEX | |
|---|---|---|
Market Cap | $78.65B | $5.61B |
Volume | 37,373,437 | 1,197,475 |
Sector | Health | Technology |
52-Week High | $203.46 | $39.69 |
52-Week Low | $22.36 | $20.01 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $74.80B | $10.63B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
OpenText (OTEX) trades at $23.595, up 1.97% today, showing strong earnings momentum with three consecutive quarterly beats. The stock trades at discounted valuations (P/E 9.01, P/S 1.1) compared to sector peers. Recent corporate actions include a $1 billion senior secured notes offering and strategic AI partnership with Cohere, while technical indicators signal near-term bearish pressure with RSI at overbought levels.
The investment case balances attractive fundamentals against technical headwinds. Strong cloud growth (22.5% bookings growth in fiscal 2026) and improving margins support upside to the $28.30 consensus target, but high debt levels and bearish technical signals warrant caution. The stock offers value opportunity for patient investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
